Eli Lilly to stop developing schizophrenia drug

Wed Aug 29, 2012 8:16am EDT

Aug 29 (Reuters) - Eli Lilly and Co said it would stop developing an experimental schizophrenia drug after a recent analysis showed that a late-stage trial on the drug was likely to fail.

Lilly said that an independent futility analysis concluded the second late-stage study on the drug was unlikely to meet the main goal of the trial.

Additionally, another mid-stage trial, which was testing the drug -- pomaglumetad methionil, or mGlu2/3 -- as an adjunctive treatment with atypical antipsychotics, also failed to meet the main study goal.

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.

California state worker Albert Jagow (L) goes over his retirement options with Calpers Retirement Program Specialist JeanAnn Kirkpatrick at the Calpers regional office in Sacramento, California October 21, 2009. Calpers, the largest U.S. public pension fund, manages retirement benefits for more than 1.6 million people, with assets comparable in value to the entire GDP of Israel. The Calpers investment portfolio had a historic drop in value, going from a peak of $250 billion in the fall of 2007 to $167 billion in March 2009, a loss of about a third during that period. It is now around $200 billion. REUTERS/Max Whittaker   (UNITED STATES) - RTXPWOZ

How to get out of debt

Financial adviser Eric Brotman offers strategies for cutting debt from student loans and elder care -- and how to avoid money woes in the first place.  Video